Abbott Laboratories Reports Positive Developments
Abbott Laboratories, a leading health care equipment and supplies company, has announced several developments in recent times. The company’s stock price has increased by 1.8% since its last earnings report.
Financial Performance
Abbott’s financial performance has been strong, with a significant increase in:
- GAAP net income
- Adjusted non-GAAP net income in the first quarter of 2025
REFLECT Studies Results
The company has announced positive data from its REFLECT studies of FreeStyle Libre continuous glucose monitoring technology. The results show:
- A significant reduction in cardiovascular disease-related hospitalizations for people with Type 1 diabetes
- Reduced hospitalizations for heart complications in adults with Type 2 diabetes on insulin
FreeStyle Libre Continuous Glucose Monitoring Technology
The REFLECT studies demonstrate the effectiveness of Abbott’s FreeStyle Libre technology in reducing hospitalizations related to cardiovascular disease and heart complications in people with diabetes.